Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia.
We describe the validation of a serum-based test developed by Rules-Based Medicine which can be used to help confirm the diagnosis of schizophrenia. In preliminary studies using multiplex immunoassay profiling technology, we identified a disease signature comprised of 51 analytes which could distinguish schizophrenia (n = 250) from control (n = 230) subjects. In the next stage, these analytes were developed as a refined 51-plex immunoassay panel for validation using a large independent cohort of schizophrenia (n = 577) and control (n = 229) subjects. The resulting test yielded an overall sensitivity of 83% and specificity of 83% with a receiver operating characteristic area under the curve (ROC-AUC) of 89%. These 51 immunoassays and the associated decision rule delivered a sensitive and specific prediction for the presence of schizophrenia in patients compared to matched healthy controls.
Institute of Biotechnology, University of Cambridge, Cambridge, UK (consultants to Rules-Based Medicine).
Emanuel
E
Schwarz
Rauf
R
Izmailov
Michael
M
Spain
Anthony
A
Barnes
James P
JP
Mapes
Paul C
PC
Guest
Hassan
H
Rahmoune
Sandra
S
Pietsch
F Markus
FM
Leweke
Matthias
M
Rothermundt
Johann
J
Steiner
Dagmar
D
Koethe
Laura
L
Kranaster
Patricia
P
Ohrmann
Thomas
T
Suslow
Yishai
Y
Levin
Bernhard
B
Bogerts
Nico Jm
NJ
van Beveren
George
G
McAllister
Natalya
N
Weber
David
D
Niebuhr
David
D
Cowan
Robert H
RH
Yolken
Sabine
S
Bahn